yasu
@cartier_yasu9
ID: 1325022352023805952
07-11-2020 10:28:58
130 Tweet
26 Followers
220 Following
æ±äº¬å€§åŠã®ç 究宀ã§ChatGPTã«é¢ããç¥èŠãå ±æããããã«äœ¿çšããè³æãå ¬éããŸãã! slideshare.net/ShotaImai3/cha⊠ã»ChatGPTã®äœ¿ãæ¹ ã»ChatGPTã®é¢é£æè¡ ã»ã³ã¢æè¡ã®åŒ·ååŠç¿,InstructGPT ãªã©ã詳ãã解説ããŸãã ãã£ãããªã®ã§,è³æã®äœæã¯ChatGPTèªäœã®åºåãäžéšäœ¿ã£ãŠæäŒã£ãŠããããŸãã
ããçš®ãåãããå ç«ãã§ãã¯ãã€ã³ãé»å®³å€ã®é©å¿ãã©ãã©ãæ¡å€§ãããŠãããé«äŸ¡ãªæ²»çãªã®ã«ãæ£è ã®è² æ ã¯ãããããã倧åã¯çšéã®è² æ ãæ¹¯æ°Žã®åŠãæ²»çã«äœ¿ãããŠããããã©ãæ¥æ¬ã®å°æ¥ã¯å€§äžå€«ãªã®ã ãããïŒ
ð¥Excellent news: KEYNOTE-966 met its primary endpoint with statistically significant & meaningful improvement in OS â Important study that underscores the value of IO in BTC -> more options after TOPAZ-1 ðThrilled to see the data AACR ESMO - Eur. Oncology OncoAlert EASL Education #LiverTwitter
æå€ãšç¥ãããŠããŸãããããã¬ãŒã³è³æãã¹ã©ã€ããªã©ã§äœ¿ãåã°ã©ããã¡ãã£ãšããæãã«ãããšã㯠â å šéšã¢ãã¯ãã«ãã â¡å°ããµã€ãºã®å°ããçœãåãéãã â¢åŒ·èª¿ãããæ°åãåã®äžã«å ¥ãã ã®ïŒã€ã®ã¹ãããã ãã§ãããããªæãã«ãªããŸãã
æè¿Chat GPTã話é¡ã§ãããèšåºå»ãæ€çŽ¢ã«äœ¿ãã®ã«ã¯ãPerplexity AIããæç¶è¯ãã§ãã èšåºã§çããçåãæ€çŽ¢ããã®ã«ã¯Googleæ€çŽ¢ãããæã£åãæ©ããæ å ±æºãæç€ºããããã確èªäœæ¥ãè¡ããããã (pubmed)ã(guideline)ãªã©ãšå ¥åãããšãåŒçšå ãæå®ããããšãã§ããŸãã
ããã®èšèªæè¡ã¯ããã¹ãŠã®ãã¯ã€ãã«ã©ãŒã®äººãã¡ã«åœ±é¿ãåã¶ã®ã§ãã€ã³ã¿ãŒãããã®é»ææããã以äžã«å€§ããªã€ã³ãã¯ãã ãšæããŸãã ä»äºãšãã£ãªã¢ãæ©ãã«åå®çŸ©ããŠããããžã·ã§ã³ãäœããã£ã³ã¹ãæ¥ãã£ãŠèªãããã ãã©ã©ãã ãããäžèªãã䟡å€ããã®èšäºã toyokeizai.net/articles/-/648âŠ
Webãµã€ãããã®æ å ±ãããç ç©¶ããšããã³ã¹ã«åºã¥ããçããæ±ããŠãæ¹ã«ãªã¹ã¹ã¡ãããã®ã Consensus âãChatGPTã®ãããªæèŠã§è³ªåãããšè€æ°ã®è«æããæç®ä»ãã§çµè«ãåºããŠãããðãèŠã€ããæ å ±ãSNSäžã§ã·ã§ã¢ã§ããã®ã倧å€äŸ¿å©ãElicitããã䜿ããããå°è±¡ã§ãã
ð¥Clinical characteristics & outcome of patients with combined hepatocellular-cholangiocarcinoma - ðªðº multicenter cohort ESMO Open doi.org/10.1016/j.esmo⊠â Our RWD on 101 pts ðvery poor prognosis ð€šwe need to do better.. NGS? ICI? -> trials.. ESMO - Eur. Oncology EASL Education #livertwitter
åãã³ããŒã¯å€§åŠã® Mushtaq Bilal, PhD å çããå«ççã« ChatGPT ã䜿çšããŠåçš¿ãå·çããã³ãã«ã€ã㊠twitter ã§ç޹ä»ããŠããã®ã§ãæ¬äººã®æ¿è«ŸãåŸãŠãç°¡åã«æ¥æ¬èªã«èš³ããŠæ²èŒèŽããŸãã plaza.umin.ac.jp/shoei05/wp/indâŠ
ð¥Second-line therapy in #PDAC with germline BRCA1/2 pathogenic variants British Journal of Cancer doi.org/10.1038/s41416⊠â ð«ð· RWD 84 pts ðPlatinum in 2nd line is better than platinum-free ð Platinum triplet upfront appears to be best ð§Early testing for BRCA will be key.. ESMO - Eur. Oncology @oncoalert
察話åAIãChatGPTãã® #ããã³ãã ã«ã€ããŠããããŠ"äžéã®åéã"ãã¶ã£ã¡ãããŸãã éåžžã«å€§äºãªèãã§ãã æè¿ããã³ãããæµè¡ã£ãŠãŸããã ãããã§ããããã ããã£ãœãé£ããããªããã³ãããšèªç¶èšèªïŒå£èªïŒã®ã¿ã§æžãããã®ã¯åãçµæã«ãªããããã§ãã
ãIFCT-1701: NivoïŒIpiã®Stop and GoæŠç¥ã åã«ãäœåºŠããã€ãŒãããããšãã£ããããªæ°ãããŸãã, NivoïŒIpi 6ã¶ææäžåŸã«ç¡å¢æªã ã£ãå Žåã«äŒè¬ã, å墿ªããå Žåã«æäžåéããæ²»çæŠç¥. NivoïŒipiã®å®å šæ§ã«æžå¿µãããæ¥æ¬ã§ã¯, éåžžã«æ°ã«ãªãç ç©¶ã§ã. 1/4 scratch-work-2af.notion.site/NSCLC-Nivo-IpiâŠ
ðåµåžã® ã²ã»ã¿ã»ã€ð 2023.06ver 瀟åµã»åµåžã¯ãéã貞ããŸãã âšãæ®é瀟åµïŒã·ãã¢åµïŒããšãã£ãŠæ®éã«ãéã貞ã瀟åµããããŸãã ã10幎éãéã貞ããŠã10幎åŸã«è¿ãããéå©ãæ¯å¹Ž5%æãããããããšããç©ã§ãã
ãåœããéãããã£ãšæãç¶ããŠãããŸãããã€ããç¶ããã®ãã°ã«ããŠãã ãããçãéã ã£ããã©ãããããã®ãªãæéãäžããŠãããŠãæ¬åœã«ããããšããæ°žé ã«åã®å®ç©ã§ãã ãïŒ.ïŒå€§éçœãæ¶ã®ç¶ãå®ç©å¥ªãããããç æŽ²åç 厩ã劻åïŒäººç ç² news.yahoo.co.jp/articles/e6f7dâŠ
â ïžããå ç«çæ³ã®RCTã«ãããæå®³äºè±¡ã®å ±åã«ãŸã€ããåé¡ ðAnn Oncol 2024 x.gd/mdyrj éèŠãªèŠç¹ã ãšæããŸã. â¶AEã®äžå®å šãªå ±å â·AEã®åéã»ã³ãŒãã£ã³ã°ã»å ±åã®çµ±äžæ§ã®æ¬ åŠ âžè¿œè·¡æéãæŽé²æéã®åœ±é¿ã®èæ ®ã®æ¬ åŠ 3ç¹ã®è©³çްã¯äžèšããªãŒ 1/4
仿¥ãžã ã§ããããªãã»ã©ããéŠãã®ç·æ§ãããŠãäœã䜿ã£ãŠããã絶察ã«èããããšæã声ãæããããã¯ã«ãžã£ã³ã®ãéŠæ°Žäœ¿ã£ãŠãããšæããŠããããã·ã£ã¯ãŒæµŽã³ããŠã¿ãããªçœãããªéŠãã§äžäººåãã®éŠæ°Žã ãªã£ãŠæã£ããããã¯å«ããªäººãããªãéŠãã§ç§ã欲ããããããªã声ãããŠããããªããã
ãç®ã§èŠããããããã©è³ã ãšèãåããªãããšããæ©ã¿ãæã£ãŠãã人ã¯å€ãã§ãã ç®ãšè³ã§è±èªã倧éã«åææåããããšã§ãç®ãšè³ã®ä¹é¢ãå°ãªããªã£ãŠããŸããã¹ã¯ãªãã(å°æ¬)ãè±èªåå¹ãèŠãªããèãã®ãè¯ãã§ããã䟿å©ãªãµã€ããéããŠã¿ãŸããâŠïŒ
åŠäŒãªã©ã§ãã¬ãŒã³ãããšãã®åäœã¯ãã¡ã€ãªãªâæžžãŽã·ãã¯ãšå€é·ããŠãããã©ã3幎ãããåããUDããžã¿ã«æç§æžäœã䜿ã£ãŠããã 匱èŠã®äººã§ãèªããããšãç®çã«éçºããããã€ãªã®ã§ããšã«ããèªã¿ãããã çµæãšããŠããã¬ãŒã³ã®åŸã«è³ªåãã³ã¡ã³ãããã ãããšãå¢ããã